Radiolabeled Peptides and Antibodies in Medicine

Abstract

Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still expanding. This group is very diverse in terms of peptide size. It contains very small structures containing several amino acids and whole antibodies. Moreover, radiolabeled peptides are diverse in terms of the binding aim and therapeutic or diagnostic applications. The majority of this class of radiotracers is utilized in oncology, where the same structure can be used in therapy and diagnostic imaging by varying the radionuclide. In this study, we collected new reports of radiolabeled peptide applications in diagnosis and therapy in oncology and other fields of medicine. Radiolabeled peptides are also increasingly being used in rheumatology, cardiac imaging, or neurology. The studies collected in this review concern new therapeutic and diagnostic procedures in humans and new structures tested on animals. We also performed an analysis of clinical trials, which concerns application of radiolabeled peptides and antibodies that were reported in the clinicaltrials.gov database between 2008 and 2018.

Imaging intact human organs with local resolution of cellular structures using hierarchical phase-contrast tomography

“…To integrate HiP-CT into such efforts, a future challenge will be the validation and extension of automated cell detection and labelling. This may necessitate the development of contrast agents 47 or of multi-modal imaging using techniques with established targeted labelling 3 . Another challenge is the computational power and storage required to handle the magnitude of data generated by HiP-CT. Whilst the hierarchical nature of HiP-CT is inherently data efficient, a single VOI through the depth of the lung captured at 6 μm/voxel still amasses ~600GB of data.…”

Bifunctional chelators for radiorhenium: past, present and future outlook

“…34,45,47 The second reason for the popularity of 188 Re is its relatively short half-life of about 17 hours. 3,32,34 Although this restricts its use to biological targeting agents with a similarly short half-life and rapid target uptake, 48 its relatively short half-life is more appropriate for therapeutic purposes as it poses a lower overall toxicity risk than 186 Re. With the increasing availability of commercial generators, the respective 188 Re radiopharmaceuticals may also conveniently be prepared directly in hospitals, even in remote locations far from nuclear reactors.…”

Preclinical assessment of Alzheimer's disease using novel designed 99mTc‐labeled RGD‐based pro‐apoptotic cyclic peptide as a promising SPECT agent

“…α v β 3 -integrin receptor highly overexpressed on AD-induced brain regions, which facilitated the binding interaction with RGD-based radiolabeled peptide analogs, and the same pattern was observed in the case of our proposed cyclic peptide-based radiotracer. [43,44]…”